Trial Profile
A Phase 1, Single-Time Blood Sample Collection Study for Pharmacogenomic Characterization of Subjects That Previously Received Namilumab and Participated in the Phase 1 PRIORA Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Jan 2018
Price :
$35
*
At a glance
- Drugs Namilumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics; Pharmacogenomic
- Sponsors Takeda
- 18 Oct 2016 Status changed from not yet recruiting to completed.
- 22 Aug 2015 New trial record